Abstract:Background: In 2003, severe acute respiratory syndrome (SARS) resulted in hundreds of infections and deaths globally. We aim to assess immunogenicity and protective efficacy of purified inactivated Vero-cell SARS vaccine in monkeys.Methods: The cultures of SARS coronavirus (SARS-CoV) BJ-01 strain infected Vero cells were inactivated with beta-propiolactone. Sequential procedures, including ultrafiltration, gel filtration and ion exchange chromatography, were performed to obtain purified inactivated SARS vaccine. The purified SARS vaccine was analyzed with electron microscope, HPLC and Western blotting. We immunized three groups of cynomolgus macaques fascicularis with adjuvant-containing purified vaccine, purified vaccine and unpurified vaccine, respectively, and a fourth group served as a control. Antibody titers were measured by plaque reduction neutralization test. The vaccinated monkeys were challenged with SARS-CoV BJ-01 strain to observe protective efficacy. Additionally, three groups of rhesus monkeys were immunized with different doses of the purified inactivated SARS vaccine (0.5, 1 and 2 mu g/time/monkey) on days 0 and 7, and the monkeys were challenged with SARS-CoV GZ-01 strain. We assessed the safety of the SARS vaccine and observed whether the antibody dependent enhancement (ADE) occurred under low levels of neutralizing antibody in rhesus.Findings: The purity of SARS vaccine was 97.6% by HPLC identification and reacted with convalescent sera of SARS patients. The purified SARS vaccine induced high levels of neutralizing antibodies and prevented the replication of SARS-CoV in monkeys. Under low levels of neutralizing antibody, no exacerbation of clinical symptoms was observed when the immunized monkeys were challenged with SARS-CoV. In this preliminary animal trial, no side effects were detected when monkeys were immunized with purified SARS vaccine either at normal or large doses.Interpretation: The purified inactivated SARS vaccine could induce high levels of neutralizing antibody, and protect the monkeys from the challenge of SARS-CoV. The SARS vaccine prepared in the study appeared to be safe in monkeys. (c) 2005 Published by Elsevier Ltd.

Purification,identification and Preliminary Application of Inactivated SARS-CoV Vaccine

Immunogenicity and Protective Efficacy in Monkeys of Purified Inactivated Vero-Cell Sars Vaccine

Preparation, Characterization and Preliminary in Vivo Studies of Inactivated Sars-Cov Vaccine

Preparation and Preliminary Application of Recombinant Severe Acute Respiratory Syndrome Coronavirus (Sars-Cov) N Protein

A Single-Step Method for Harvesting Influenza Viral Particles from MDCK Cell Culture Supernatant with High Yield and Effective Impurity Removal

Efficient Purification of Cell Culture-Derived Classical Swine Fever Virus by Ultrafiltration and Size-Exclusion Chromatography

Expression and purification of recombinant SARS-CoV-2 nucleocapsid protein in inclusion bodies and its application in serological detection

[Expression and Purification of Recombinant N-terminal Protein of SARS S1 Subunit Expressed in E. Coli].

Inactivated Sars-Cov Vaccine Prepared from Whole Virus Induces A High Level of Neutralizing Antibodies in Balb/C Mice

Preparation and identification of a single domain antibody specific for adenovirus vectors and its application to the immunoaffinity purification of adenoviruses

Intranasal Immunization with Inactivated SARS-CoV (Sars-Associated Coronavirus) Induced Local and Serum Antibodies in Mice.

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Cloning, Expression, Purification of a Fusion Protein of SARS-CoV Nucleocapsid and Spike Protein Fragments and Its Immunological Characteristics

Enterovirus71 Virus-Like Particles Produced from Insect Cells and Purified by Multistep Chromatography Elicit Strong Humoral Immune Responses in Mice

Identification and Characterization of Novel Neutralizing Epitopes in the Receptor-Binding Domain of SARS-CoV Spike Protein: Revealing the Critical Antigenic Determinants in Inactivated SARS-CoV Vaccine.

Isolation and Identification of an Scfv Antibody Against Nucleocapsid Protein of SARS-CoV.

A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9)

The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro

Low Toxicity and High Immunogenicity of an Inactivated Vaccine Candidate Against COVID-19 in Different Animal Models.

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Validation Test on Inactivation of Rabies Vaccine: Development of Cell Culture Method